ADA Consensus Report - MASLD in People with Diabetes - The Need for Screening and Early Intervention

<h2 id="background">Background</h2><ul><li><strong>Increased risk of MASLD:</strong> Rising rates of obesity and diabetes significantly contribute to the increased risk of developing MASLD.</li><li><strong>MASLD screening:</strong> Early identification of high-risk individuals is essential for effective and timely management.</li><li><strong>Varied data:</strong> Variability in MASLD prevalence is largely attributed to evolving definitions and diagnostic standards.</li></ul><h2 id="aim">Aim</h2><ul><li>Consensus statement is developed to guide healthcare professions.</li></ul><h2 id="challenges">Challenges</h2><ul><li>Inappropriate reporting: Current prevalence estimates may not accurately reflect the true burden of disease, particularly in high-risk populations.</li><li>Variable estimates: Variations in symptoms and diagnostic approaches contribute to inconsistent prevalence rates across epidemiological studies.</li></ul><h2 id="goals">Goals of the Consensus</h2><ul><li>Identifying at-risk individuals</li><li>Effective treatment strategies Promoting clinical reasearch in MASLD</li></ul><h2 id="clinical-implications">Clinical Implications of MASLD</h2><p style="text-align:center;"><img src="https://cdn.megawecare.com/GHBY/Internal-Images/clinical-implications-of-masld-table-1.webp" alt="CLINICAL IMPLICATIONS OF MASLD" width="1081" height="481"></p><h2 id="masld-nomenclature">MASLD Nomenclature</h2><figure class="image"><img style="aspect-ratio:1108/339;" src="https://cdn.megawecare.com/GHBY/Internal-Images/nomenclature-changes-in-sld.webp" alt="MASLD NOMENCLATURE" width="1108" height="339"></figure><figure class="image"><img style="aspect-ratio:1102/307;" src="https://cdn.megawecare.com/GHBY/Internal-Images/nomenclature-changes-in-sld-table-2.webp" alt=" MASLD NOMENCLATURE" width="1102" height="307"></figure><h2 id="diagnosis-criteria">Diagnosis Criteria</h2><p style="text-align:center;"><img src="https://cdn.megawecare.com/GHBY/Internal-Images/diagnosis-criteria.webp" alt="DIAGNOSIS CRITERIA" width="1087" height="373"></p><figure class="image"><img style="aspect-ratio:1111/568;" src="https://cdn.megawecare.com/GHBY/Internal-Images/diagnostic-algorithm-for-risk.webp" alt="DIAGNOSIS CRITERIA" width="1111" height="568"></figure><figure class="image"><img style="aspect-ratio:1096/637;" src="https://cdn.megawecare.com/GHBY/Internal-Images/preferred-tests-table-4.webp" width="1096" height="637"></figure><h2 id="masld-treatment">MASLD Treatment</h2><figure class="image"><img style="aspect-ratio:1090/586;" src="https://cdn.megawecare.com/GHBY/Internal-Images/lifestyle-modifications-for-individuals.webp" width="1090" height="586"></figure><figure class="image"><img style="aspect-ratio:1105/622;" src="https://cdn.megawecare.com/GHBY/Internal-Images/maslld-treatment-algorithm.webp" width="1105" height="622"></figure><figure class="image"><img style="aspect-ratio:846/547;" src="https://cdn.megawecare.com/GHBY/Internal-Images/liver-monitoring-for-care-of-individuals.webp" width="846" height="547"></figure><h2 id="conclusion">Conclusion</h2><ul><li>Prediabetes or type 2 diabetes have the highest risk of developing MASLD.</li><li>One in five people with type 2 diabetes have clinically significant fibrosis and are at high<br>risk of developing cirrhosis from MASLD (i.e., has at-risk MASH).</li><li>MASLD is also associated with increased risk of HCC as well as extrahepatic malignancies and cardiovascular disease.</li><li>Individuals with prediabetes or type 2 diabetes should undergo a two-step risk stratification process—using FIB-4 with or without LSM—to evaluate their likelihood of having at-risk MASH with clinically significant liver fibrosis or cirrhosis.</li><li>This consensus report emphasizes that early detection and appropriate management can halt the progression of liver fibrosis to cirrhosis in individuals with prediabetes or type 2 diabetes—similar to the established approach for preventing diabetes-related microvascular complications (such as retinopathy, nephropathy, or neuropathy) and cardiovascular disease.</li><li>This initiative aims to drive a transformation in clinical practice—ultimately improving outcomes and quality of life for individuals living with diabetes and MASLD with interprofessional care teams, clinician awareness and engagement, promoting education, establishing effective care models, and implementing proactive public health policies.</li></ul>

ADA MASLD

<ul><li><a href="#background">Background</a></li><li><a href="#aim">Aim</a></li><li><a href="#challenges">Challenges</a></li><li><a href="#goals">Goals of the Consensus</a></li><li><a href="#clinical-implications">Clinical Implications of MASLD</a></li><li><a href="#masld-nomenclature">MASLD Nomenclature</a></li><li><a href="#diagnosis-criteria">Diagnosis Criteria</a></li><li><a href="#masld-treatment">MASLD Treatment</a></li><li><a href="#conclusion">Conclusion</a></li></ul><p>&nbsp;</p><p>&nbsp;</p>

ADA Consensus Report - MASLD in People with Diabetes - The Need for Screening and Early Intervention

Reference